肝动脉灌注化疗在中晚期肝癌联合治疗中的作用
The Role of Hepatic Arterial Infusion Chemotherapy in the Combination Therapy of Advanced Hepatocellular Carcinoma
DOI: 10.12677/ACM.2022.123271, PDF,    国家自然科学基金支持
作者: 苏 涛*, 吴传新#：重庆医科大学附属第二医院肝胆外科，重庆；孙 航：重庆医科大学附属第二医院病毒性肝炎研究所，重庆
关键词: 中晚期肝细胞癌；肝动脉灌注化疗；联合治疗；Advanced Hepatocellular Carcinoma； Hepatic Arterial Infusion Chemotherapy； Combination Therapy
摘要: 我国肝癌初诊时大部分即为中晚期，绝大多数中晚期肝癌病人已不宜首选手术切除，而应接受以非手术局部治疗和系统治疗为主的治疗。近年来肝动脉灌注化疗(Hepatic artery infusion chemotherapy, HAIC)等局部治疗手段取得显著进展。HAIC在缩小肿瘤、控制癌栓方面获得较以往更好的效果，病人生存也得到改善。目前肝癌的治疗趋势以联合治疗为主，已有的研究均表明，肝癌的联合治疗方案明显优于单一治疗。因此本文就近年HAIC在中晚期肝癌联合治疗中的作用进行综述。
Abstract: Chinese patients with hepatocellular carcinoma (HCC) are often diagnosed at advanced stage. The vast majority of patients with advanced hepatocellular carcinoma (aHCC) could not receive radical resection, but should receive local treatment and systematic therapy. In recent years, local treatment methods such as hepatic artery infusion chemotherapy (HAIC) have made remarkable progress. HAIC has achieved better results in reducing tumor and controlling portal vein tumor thrombus than before, and the survival of patients has also been improved. At present, the treatment trend of HCC is mainly combination therapy. Existing studies have shown that the combination therapy of HCC is significantly better than single one. Therefore, this paper reviews the role of HAIC in the combination therapy of aHCC in recent years.
文章引用：苏涛, 孙航, 吴传新. 肝动脉灌注化疗在中晚期肝癌联合治疗中的作用[J]. 临床医学进展, 2022, 12(3): 1881-1887. https://doi.org/10.12677/ACM.2022.123271

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Forner, A., Reig, M. and Bruix J. (2018) Hepatocellular Carcinoma. Lancet, 391, 1301-1314. [Google Scholar] [CrossRef] 
[3] Yang, J.D., Hainaut, P., Gores, G.J., Amadou, A., Plymoth, A. and Roberts, L.R. (2019) A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nature Reviews Gastroenterology & Hepatology, 16, 589-604. [Google Scholar] [CrossRef] [PubMed]
[4] Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., et al. (2020) Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 9, 682-720. [Google Scholar] [CrossRef] [PubMed]
[5] Park, J.W., Chen, M., Colombo, M., et al. (2015) Global Patterns of Hepatocellular Carcinoma Management from Diagnosis to Death: The BRIDGE Study. Liver International, 35, 2155-2166. [Google Scholar] [CrossRef] [PubMed]
[6] Ando, E., Tanaka, M., Yamashita, F., Kuromatsu, R., Yutani, S., Fukumori, K., et al. (2002) Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Analysis of 48 Cases. Cancer, 95, 588-595. [Google Scholar] [CrossRef] [PubMed]
[7] Kudo, M., Matsui, O., Izumi, N., Iijima, H., Kadoya, M., Ima,i Y., et al. (2014) JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update By the Liver Cancer Study Group of Japan. Liver Cancer, 3, 458-468. [Google Scholar] [CrossRef] [PubMed]
[8] Qin, S., Bai, Y., Lim, H.Y., Thongprasert, S., Chao, Y., Fan, J., et al. (2013) Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/leucovorin versus Doxorubicin as Palliative Chemotherapy in Patients with Advanced Hepatocellular Carcinoma from Asia. Journal of Clinical Oncology, 31, 3501-3508. [Google Scholar] [CrossRef] 
[9] Lyu, N., Kong, Y., Mu, L., Lin, Y., Li, J., Liu, Y., et al. (2018) Hepatic Arterial Infusion of Oxaliplatin Plus Fluorouracil/leucovorin vs. Sorafenib for Advanced Hepatocellular Carcinoma. Journal of Hepatology, 69, 60-69. [Google Scholar] [CrossRef] [PubMed]
[10] He, M.K., Le, Y., Li, Q.J., Yu, Z.S., Li, S.H., Wei, W., et al. (2017) Hepatic Artery Infusion Chemotherapy Using MFOLFOX versus Transarterial Chemoembolization for Massive Unresectable Hepatocellular Carcinoma: A Prospective Non-Randomized Study. Chinese Journal of Cancer, 36, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
[11] 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版) [J]. 中国实用外科杂志, 2021, 41(6): 618-632.
[12] Ahn, Y.E., Suh, S.J., Yim, H.J., Seo, Y.S., Yoon, E.L., Kim, T.H., et al. (2021) Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Gut Liver, 15, 284-294. [Google Scholar] [CrossRef] [PubMed]
[13] Choi, J.H., Chung, W.J., Bae, S.H., Song, D.S., Song, M.J., Kim, Y.S., et al. (2018) Randomized, Prospective, Comparative Study On the Effects and Safety of Sorafenib Vs. Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancer Chemotherapy and Pharmacology, 82, 469-478. [Google Scholar] [CrossRef] [PubMed]
[14] Abdelmaksoud, A.H.K., Abdelaziz, A.O., Nabeel, M.M., Hamza, I., Elbaz, T.M., Shousha, H.I., et al. (2021) Hepatic Arterial Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: A Case-Control Study. Clinical Radiology, 76, 709.E1-709.E6. [Google Scholar] [CrossRef] [PubMed]
[15] 中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国抗癌协会肝癌专业委员会, 北京医学会外科学分会肝脏学组, 等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版) [J]. 肝癌电子杂志, 2021, 8(2): 6-15.
[16] 李建基, 杨哲, 黄赞松. 原发性肝癌分子靶向治疗基础与临床研究进展[J]. 世界华人消化杂志, 2019, 27(10): 643-650.
[17] Poggi, G., Montagna, B., Melchiorre, F., Quaretti, P., Delmonte, A., Riccardi, A., et al. (2011) Hepatic Intra-Arterial Cetuximab in Combination with 5-Fluorouracil and Cisplatin as Salvage Treatment for Sorafenib-Refractory Hepatocellular Carcinoma. Anticancer Research, 31, 3927-3933.
[18] Nagai, H., Mukozu, T., Ogino, Y.U., Matsui, D., Matsui, T., Wakui, N., et al. (2015) Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Anticancer Research, 35, 2269-2277.
[19] He, M., Li, Q., Zou, R., Shen, J., Fang, W., Tan, G., et al. (2019) Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncology, 5, 953-960. [Google Scholar] [CrossRef] [PubMed]
[20] 都亚薇, 张宁宁, 陆伟. 肝癌免疫治疗的研究现状及展望[J]. 实用肿瘤杂志, 2021, 36(5):393-398.
[21] He, M.K., Liang, R.B., Zhao, Y., Xu, Y.J., Chen, H.W., Zhou, Y.M., et al. (2021) Lenvatinib, Toripalimab, Plus Hepatic Arterial Infusion Chemotherapy versus Lenvatinib Alone for Advanced Hepatocellular Carcinoma. Therapeutic Advances in Medical Oncology, 13, Article ID: 17588359211002720. [Google Scholar] [CrossRef] [PubMed]
[22] Xu, Y.J., Lai, Z.C., He, M.K., Bu, X.Y., Chen, H.W., Zhou, Y.M., et al. (2021) Toripalimab Combined with Hepatic Arterial Infusion Chemotherapy versus Lenvatinib for Advanced Hepatocellular Carcinoma. Technology in Cancer Research & Treatment, 20, Article ID: 15330338211063848. [Google Scholar] [CrossRef] [PubMed]
[23] Kamiyama, T., Nakanishi, K., Yokoo, H., Tahara, M., Nakagawa, T., Kamachi, H., et al. (2007) Efficacy of Preoperative Radiotherapy to Portal Vein Tumor Thrombus in the Main Trunk or First Branch in Patients with Hepatocellular Carcinoma. International Journal of Clinical Oncology, 12, 363-368. [Google Scholar] [CrossRef] [PubMed]
[24] Kodama, K., Kawaoka, T., Aikata, H., Uchikawa, S., Nishida, Y., Inagaki, Y., et al. (2018) Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. Oncology, 94, 215-222. [Google Scholar] [CrossRef] [PubMed]
[25] Byun, H.K., Kim, H.J., Im, Y.R., Kim, D.Y., Han, K.H. and Seong, J. (2019) Dose Escalation by Intensity Modulated Radiotherapy in Liver-Directed Concurrent Chemoradiotherapy for Locally Advanced BCLC Stage C Hepatocellular Carcinoma. Radiotherapy and Oncology, 133, 1-8. [Google Scholar] [CrossRef] [PubMed]

为你推荐